Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

823 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Towards a universal second-line fixed-dose combination ART.
Boyd MA, Cooper DA, Gilks CF. Boyd MA, et al. Among authors: cooper da. Lancet HIV. 2018 Jan;5(1):e3-e5. doi: 10.1016/S2352-3018(17)30180-7. Epub 2017 Oct 6. Lancet HIV. 2018. PMID: 28993181 No abstract available.
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Boyd MA, Moore CL, Molina JM, Wood R, Madero JS, Wolff M, Ruxrungtham K, Losso M, Renjifo B, Teppler H, Kelleher AD, Amin J, Emery S, Cooper DA; SECOND-LINE study group. Boyd MA, et al. Among authors: cooper da. Lancet HIV. 2015 Feb;2(2):e42-51. doi: 10.1016/S2352-3018(14)00061-7. Epub 2015 Jan 20. Lancet HIV. 2015. PMID: 26424460 Clinical Trial.
Tenofovir alafenamide: safer, but questions remain.
Boyd MA, Cooper DA. Boyd MA, et al. Among authors: cooper da. Lancet HIV. 2016 Apr;3(4):e148-9. doi: 10.1016/S2352-3018(16)00039-4. Epub 2016 Mar 14. Lancet HIV. 2016. PMID: 27036985 No abstract available.
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA, Amin J, Mallon PW, Kumarasamy N, Lombaard J, Wood R, Chetchotisakd P, Phanuphak P, Mohapi L, Azwa I, Belloso WH, Molina JM, Hoy J, Moore CL, Emery S, Cooper DA; SECOND-LINE Study Group. Boyd MA, et al. Among authors: cooper da. Lancet HIV. 2017 Jan;4(1):e13-e20. doi: 10.1016/S2352-3018(16)30189-8. Epub 2016 Nov 1. Lancet HIV. 2017. PMID: 27815068 Clinical Trial.
Long-acting injectable ART: next revolution in HIV?
Boyd MA, Cooper DA. Boyd MA, et al. Among authors: cooper da. Lancet. 2017 Sep 23;390(10101):1468-1470. doi: 10.1016/S0140-6736(17)31962-1. Epub 2017 Jul 24. Lancet. 2017. PMID: 28750936 No abstract available.
Combination ART: are two drugs as good as three?
Boyd MA, Cooper DA. Boyd MA, et al. Among authors: cooper da. Lancet. 2018 Mar 3;391(10123):817-819. doi: 10.1016/S0140-6736(18)30008-4. Epub 2018 Jan 6. Lancet. 2018. PMID: 29310898 No abstract available.
823 results